336 results
Page 9 of 17
6-K
EX-99.1
b69oc 35w2
5 Feb 13
Teva Announces First Patient Enrolled In Largest Clinical Study to Date Evaluating Azilect® for Mild Cognitive Impairment In Parkinson’s Disease
12:00am
6-K
EX-99.1
ln8fe9pr
31 Jan 13
Teva Announces Termination of Agreements with Curetech
12:00am
6-K
EX-99.1
g9ysm
23 Jan 13
Live Filing
12:00am
6-K
EX-99.1
1yiqw6j1yail l9
18 Dec 12
Live Filing
12:00am
6-K
EX-99.1
m5k3ybr6 m2ank
18 Dec 12
Teva Signs New $3.0 Billion Syndicated Revolving Credit Facility
12:00am
6-K
EX-99.1
fuj7bx7vkxmm6
17 Dec 12
Teva Enters Agreement with Handok to Establish Business Venture with Significant Presence in Korean Pharmaceutical Market
12:00am
6-K
EX-99.1
m0bw 7h7rgt
14 Dec 12
Teva Announces Pricing of $2.0 Billion of Senior Notes
12:00am
424B5
6g143ld
14 Dec 12
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
ag4dg2 3qh7exyp
13 Dec 12
Teva Receives A- Rating from Fitch Ratings with a Stable Outlook
12:00am
424B5
fe5b1o uqail2n
13 Dec 12
Prospectus supplement for primary offering
12:00am
6-K
EX-99
ooe nj0vn44tr1hy
11 Dec 12
Live Filing
12:00am
6-K
x3urfdq7df
30 Nov 12
Teva Pharmaceutical Industries Limited 6-K
12:00am
6-K
EX-99.1
qne2to88fvgdb4u8r
1 Nov 12
Teva Reports Third Quarter 2012 Results
12:00am
6-K
ju1bvw51ear b201dnn
1 Nov 12
Current report (foreign)
12:00am
6-K
EX-99.1
9y2cwdj0lp55pht
26 Oct 12
Teva Receives Approval for Synribotm(omacetaxine Mepesuccinate) for Injection
12:00am
6-K
EX-99.1
5u4p uou9jtt
25 Oct 12
Live Filing
12:00am
6-K
EX-99.1
1yfsdwv
25 Oct 12
Live Filing
12:00am
6-K
EX-99.1
w80iv1y jz3zdf3
22 Oct 12
PHASE IIa LAQUINIMOD TRIAL RESULTS SHOW POSITIVE DATA FOR POTENTIAL USE IN ACTIVE CROHN’S DISEASE
12:00am
6-K
EX-99.1
clsedw7vvs5v3vsm8of8
18 Oct 12
Teva Women’s Health, Inc. to Present New Data at the 68th Annual Meeting of the American Society for Reproductive Medicine
12:00am
6-K
EX-99.1
fwxpgwcy
10 Oct 12
New Data Presented at the 28TH Ectrims Congress Showcase Teva’s Ongoing Commitment to Multiple Sclerosis Research
12:00am